NCT04183881 is a Phase 4 clinical trial of Brodalumab 210mg SC in Psoriasis Vulgaris, sponsored by Kyowa Kirin Co., Ltd..

Who is sponsoring NCT04183881?

NCT04183881 is sponsored by Kyowa Kirin Co., Ltd..

What drugs are being tested in NCT04183881?

Interventions in NCT04183881: Brodalumab 210mg SC.

What condition does NCT04183881 study?

NCT04183881 studies Psoriasis Vulgaris, Psoriatic Arthritis, Pustular; Psoriasis, Palmaris Et Plantaris, Psoriatic Erythroderma.

Is NCT04183881 still recruiting?

NCT04183881 is currently completed. Last updated 9 December 2019.

Last reviewed 2019-12-09 · How we verify

NCT04183881

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase 4 Clinical Study of Brodalumab

Completed Phase 4 Last updated 9 December 2019

What this trial tests

Phase 4 trial testing Brodalumab 210mg SC in Psoriasis Vulgaris in 138 participants. Completed in 24 July 2017.

Timeline

4 July 2016

Primary endpoint
10 January 2017

24 July 2017

Quick facts

Lead sponsor	Kyowa Kirin Co., Ltd.
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	138
Start date	4 July 2016
Primary completion	10 January 2017
Estimated completion	24 July 2017
Sites	1 location across Japan

Drugs / interventions tested

Brodalumab 210mg SC — full drug profile →

Conditions studied

Psoriasis Vulgaris — all drugs for Psoriasis Vulgaris →
Psoriatic Arthritis — all drugs for Psoriatic Arthritis →
Pustular; Psoriasis, Palmaris Et Plantaris — all drugs for Pustular; Psoriasis, Palmaris Et Plantaris →
Psoriatic Erythroderma — all drugs for Psoriatic Erythroderma →

Sponsor

Kyowa Kirin Co., Ltd. — full company profile →

Who can join

18 and older, any sex, with Psoriasis Vulgaris or Psoriatic Arthritis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study \[4827-005 (post market)\] is designed to evaluate the safety and efficacy of long-term exposure to brodalumab in subjects with plaque psoriasis (psoriasis vulgaris, psoriatic arthritis) who have completed Study 4827-003 (Study 003) and in subjects with pustular psoriasis (generalized) or psoriatic erythroderma who have completed the Study 4827-004 (Study 004). 4827-005 study was conducted as phase 3 clinical trial until July 4th 2016 (approval date in Japan). After that date 4827-005 study was switched to phase 4 study.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Much More Than IL-17A: Cytokines of the IL-17 Family Between Microbiota and Cancer.
Brevi A, Cogrossi LL, Grazia G, Masciovecchio D, et al · · 2020 · cited 81× · PMID 33244315 · DOI 10.3389/fimmu.2020.565470
Interactions between neutrophils and T-helper 17 cells.
Fan X, Shu P, Wang Y, Ji N, et al · · 2023 · cited 51× · PMID 37920459 · DOI 10.3389/fimmu.2023.1279837
Pustular Psoriasis: From Pathophysiology to Treatment.
Genovese G, Moltrasio C, Cassano N, Maronese CA, et al · · 2021 · cited 40× · PMID 34944562 · DOI 10.3390/biomedicines9121746
Relationship between serum trough levels and efficacy of brodalumab from a post hoc exploratory analysis of a Japanese study in patients with plaque psoriasis.
Yamaguchi Y, Kanai Y, Kitabayashi H, Okada H, et al · · 2021 · cited 2× · PMID 33161605 · DOI 10.1111/1346-8138.15690

Verify or expand the search:

Other recruiting trials for Psoriasis Vulgaris

Currently open trials in the same condition.

NCT07426120 — Efficacy and Safety of a Botanical Total Coumarin (TC) Cream in Treating Patients With Psoriasis Vulgaris (PLANTCOAT-III · Phase 3 · recruiting
NCT07320872 — Correlation Between Vaspin Gene Polymorphism and Serum Vaspin Levels in Psoriasis Vulgaris · recruiting
NCT06398106 — Proactive TDM Versus Standard Use of Biologics in Psoriasis · Phase 4 · recruiting
NCT05185258 — Residual Disease MEMory in PSOriasis Skin During EnstiLAR® and Narrow-band Ultraviolet B Therapy: The MEMPSOLAR Study · Phase 4 · active not recruiting
NCT04950218 — Prevalence and Risk Factors asSOciated With CArdiac comorbiDIty in psoriAsis · recruiting

Other Kyowa Kirin Co., Ltd. trials

Trials by the same sponsor.

NCT06926491 — Evaluate the Efficacy and Safety of KK8398 in Patients With Achondroplasia（AOBA Study） · Phase 3 · recruiting
NCT06812104 — Clinical Trial of KK2845 in Patients With Relapsed or Refractory Acute Myeloid Leukemia · Phase 1 · recruiting
NCT06525636 — A First-in-human Study of KK8123 in Adults With X-linked Hypophosphatemia · Phase 1, PHASE2 · recruiting
NCT06116890 — Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration · Phase 2 · active not recruiting
NCT06116916 — Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema · Phase 2 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04183881 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Kyowa Kirin Co., Ltd.
Last refreshed: 9 December 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04183881.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing